Jaguar Animal Health to Present at the 2015 LD Micro Conference on December 3rd in Los Angeles

SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, announced today that Steven King, Ph.D., Executive Vice
President of Sustainable Supply, Ethnobotanical Research and IP, will
present at the upcoming LD Micro Conference at the Luxe Sunset Boulevard
Hotel in Los Angeles on Thursday, December 3, 2015 at 2:00pm PT (5:00pm
ET).

The event will be available via live audio webcast and archived replay
on Jaguar’s investor
relations website
.

Jaguar management will be available for one-on-one meetings during the
conference. To schedule a meeting, please contact LD Micro at chris@ldmicro.com
or KCSA Strategic Communications at jaguar@kcsa.com.

This December Jaguar will be launching its Neonorm Foal
product at the American Association of Equine Practitioners Annual
Convention in Las Vegas from December 5-9th. Neonorm Foal is
a non-drug equine product comprised of an orally-administered paste
formulation of a standardized botanical extract derived from the Croton
lechleri
tree, in combination with a third-party probiotic.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia is Jaguar’s
lead prescription drug product candidate for the treatment of various
forms of diarrhea in dogs. Canalevia is a canine-specific
formulation of crofelemer, an active pharmaceutical ingredient isolated
and purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm Calf and Neonorm Foal are the Company’s
lead non-drug products. Neonorm is a standardized botanical
extract derived from the Croton lechleri tree. Canalevia
and Neonorm are distinct products that act at the same last
step in a physiological pathway generally present in mammals. Jaguar has
nine active investigational new animal drug applications, or INADs,
filed with the FDA and intends to develop species-specific formulations
of Neonorm in six additional target species, and
formulations of Canalevia™ for cats, horses and dogs.

For more information, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the expected commercial
launch of Neonorm Foal this December, Jaguar’s intention to
develop species-specific formulations of Neonorm in
additional target species, and the Company’s plan to develop
formulations of Canalevia for cats, horses and dogs. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or
other similar expressions. The forward-looking statements in this
release are only predictions. Jaguar has based these forward-looking
statements largely on its current expectations and projections about
future events. These forward-looking statements speak only as of the
date of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of any
new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

Contacts

KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
Allison
Soss, 212-896-1267
asoss@kcsa.com